Developing innovative precision immunotherapies for the treatment of Progressive Supranuclear Palsy and Alzheimer’s disease
previous arrow
next arrow
Slider

TauC3 Biologics Limited (TC3B) is a British biotechnology company developing precision immunotherapy to address an important unmet medical need, namely, the category of neurodegenerative diseases known as tauopathies.  These conditions, which include Alzheimer’s disease and progressive supranuclear palsy (PSP), among others, involve deposition of abnormal forms of the protein tau in the brain.  TC3B’s initial focus is on PSP, and its lead therapeutic candidate, TBL-100, is an exceptionally potent and highly specific monoclonal antibody that targets the noxious tau fragment tauC3.